Upload
others
View
4
Download
0
Embed Size (px)
Citation preview
OBJECTIVES:• Discuss Afirma Genomic Sequencing Classifier’s (GSC) impact in the
management of indeterminate thyroid nodules • Review initial Afirma GSC clinical experience data • Unveil the new Xpression Atlas
Program sponsored by Veracyte, Inc., provider of the Afirma Thyroid FNA Analysis
C841.1.1802
Giulia C. Kennedy, PhDChief Scientific and Medical OfficerVeracyte, Inc.
Richard T. Kloos, MDSenior Medical Director EndocrinologyVeracyte, Inc.
Christian Nasr, MD Staff Endocrinologist Medical Director, Thyroid CenterCleveland Clinic
SATURDAY, MARCH 171:00–2:00 PMExpo Theater 2030Boxed lunches will be served. Space is limited. First come, first served.
JOIN US FOR A SPECIAL PRESENTATION:Evolving the Standard of Care— A Review of Afirma GSC Experience Data andIntroducing the New Xpression Atlas